Document is current
Any future updates will be listed below
-
Authors
Waitzberg, Dan https://orcid.org/0000-0002-9196-9372
Guarner, Francisco https://orcid.org/0000-0002-4051-0836
Hojsak, Iva https://orcid.org/0000-0003-3262-5964
Ianiro, Gianluca https://orcid.org/0000-0002-8318-0515
Polk, D. Brent https://orcid.org/0000-0001-6680-1554
Sokol, Harry https://orcid.org/0000-0002-2914-1822
-
Funding
Funding for this research was provided by:
Biocodex SAS
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 5 January 2024
First Online: 30 January 2024
Declarations
:
: Dan Waitzberg has received grants from Biocodex, Sanofi, Apsen, and Farmoquimica. He serves as Scientific Director of Bioma4me. Francisco Guarner declares board membership or consultancy fees from Instituto Danone, Biocodex Microbiota Foundation, AB-Biotics, Actial Farmaceutica and Menarini; research support from Abbvie, Takeda and Clasado. Iva Hojsak has received speaker’s fees from BioGaia, Biocodex, Abbott, Nestle, Sandoz, Takeda and Oktal Pharma and consultancy fees from Biocodex and Abbott. Gianluca Ianiro has received speaker’s fees from Alfa Sigma, Biocodex, Illumina, Malesci, Sofar, Tillotts Pharma and Zambon and consultancy/advisory board fees from Biocodex, Ferring, Malesci and Tillots Pharma. Brent Polk is the Chair of the Board of Trustees of the Crohn’s & Colitis Foundation, otherwise nothing to declare. Harry Sokol reports lecture fees, board membership, or consultancy from Amgen, Fresenius, IPSEN, Actial, Astellas, Danone, THAC, Biose, BiomX, Eligo, Immusmol, Adare, Nestle, Ferring, MSD, Bledina, Pfizer, Biocodex, BMS, Bromatech, Gilead, Janssen, Mayoli, Roche, Sanofi, Servier, Takeda and Abbvie. He has stocks in Enterome Bioscience and is a co-founder of Exeliom Biosciences.
: This article is based on previously published studies and does not contain any new studies with human participants or animals performed by any of the authors.
